Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Sosei Group Corporation: Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma | 43 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 27 March 2024 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the... ► Artikel lesen | |
21.03. | Sosei Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel Disease | 387 | AFX News | LONDON (dpa-AFX) - Sosei Group Corp. said it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in... ► Artikel lesen | |
21.03. | Sosei Group Corporation: Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease | 65 | GlobeNewswire (Europe) | HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 - Sosei Group Corporation ("Sosei... ► Artikel lesen | |
21.03. | Sosei Group Corporation: Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease | 59 | GlobeNewswire (Europe) | GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy... ► Artikel lesen | |
11.03. | Boehringer, Sosei Heptares team up in schizophrenia drug deal | 9 | BioPharma Dive | ||
11.03. | Boehringer Ingelheim Places €25M Bet on Sosei's Novel Approach to Schizophrenia | 9 | MedCity News | ||
11.03. | Boehringer, Sosei Heptares Partner on Schizophrenia Precision Treatment | 3 | Contract Pharma | ||
11.03. | Boehringer boosts schizophrenia strategy with €25M upfront for option on Sosei's GPR52 agonists | 3 | FierceBiotech | ||
11.03. | Boehringer licenses Sosei schizophrenia drugs in €755m deal | 2 | pharmaphorum | ||
11.03. | Boehringer and Sosei Heptares partner on schizophrenia treatment | 1 | Pharmaceutical Technology | ||
11.03. | Sosei Group Corporation: Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia | 124 | GlobeNewswire (Europe) | Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive... ► Artikel lesen | |
06.03. | Sosei Heptares Earns $2.5M Formosa Milestone | 1 | Contract Pharma | ||
06.03. | Sosei Group Corporation: Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals | 637 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 6 March 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has received approval... ► Artikel lesen | |
16.02. | Sosei ushers in new era with Nxera Pharma name change | 2 | FiercePharma | ||
16.02. | Sosei Group Corporation: Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office | 151 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 16 February 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of... ► Artikel lesen | |
13.02. | Sosei Group reports FY results | 1 | Seeking Alpha | ||
13.02. | Sosei Heptares reports mixed annual results, plans for growth | 1 | Investing.com | ||
13.02. | Sosei Group Corporation: Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023 | 136 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 13 February 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated... ► Artikel lesen | |
22.01. | Sosei Group Corporation: Sosei Heptares Webinar Presentation for FY2023 Financial Results | 2 | GlobeNewswire (USA) | ||
05.01. | Sosei Group Corporation: Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer | 534 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 5 January 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 25,750 | 0,00 % | Astellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In China | BEIJING (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced that China's National Medical Products Administration or NMPA has accepted the supplemental Biologics License Application or sBLA for... ► Artikel lesen | |
NOVARTIS | 89,75 | +1,36 % | EQS-News: MorphoSys AG: MorphoSys gibt US-Kartellfreigabe der geplanten Übernahme durch Novartis gemäß HSR Act bekannt | EQS-News: MorphoSys AG
/ Schlagwort(e): Sonstiges
MorphoSys gibt US-Kartellfreigabe der geplanten Übernahme durch Novartis gemäß HSR Act bekannt
22.03.2024 / 07:30 CET/CEST
Für... ► Artikel lesen | |
GILEAD SCIENCES | 68,20 | +0,09 % | Kurs von Gilead Sciences steigt etwas (68,1479 €) | Am US-amerikanischen Aktienmarkt liegt der Anteilsschein von Gilead Sciences aktuell im Plus. Der jüngste Kurs betrug 73,55 US-Dollar. Am Aktienmarkt liegt die Gilead Sciences-Aktie gegenwärtig im Plus.... ► Artikel lesen | |
SANOFI | 89,79 | +0,04 % | Minimale Kursveränderung bei Sanofi SA-Aktie (88,97 €) | Der Kurs der der Sanofi SA-Aktie kommt kaum von der Stelle. Das Papier notiert zur Stunde bei 88,97 Euro. Der Kurs der Aktie von Sanofi SA zeigt sich aktuell kaum verändert im Vergleich zu der letzten... ► Artikel lesen | |
ABBVIE | 168,80 | +0,06 % | Kurs der AbbVie-Aktie verharrt auf Vortags-Niveau (165,3623 €) | Wenig Kursbewegung gegenwärtig bei der Aktie von AbbVie . Der jüngste Kurs betrug 179,17 US-Dollar. Kaum auffällig ist aktuell an der Börse der Kurs von AbbVie. Das Papier liegt mit 0,36 Prozent im... ► Artikel lesen | |
ROCHE | 235,70 | +1,72 % | DEUTSCHE BANK RESEARCH stuft ROCHE HOLDINGS AG auf 'Sell' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Roche auf "Sell" mit einem Kursziel von 215 Franken belassen. Klinische Daten zum Medikament Enspryng zur Behandlung der... ► Artikel lesen | |
ABBOTT LABORATORIES | 105,26 | -0,09 % | Eli Lilly climbs on win for rival weight-loss drug, and we still feel good about Abbott Labs | ||
HAEMATO | 16,600 | -0,60 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 05.03.2024 | The following instruments on XETRA do have their first trading 05.03.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 05.03.2024
Aktien
1 DE000A289VV1 HAEMATO AG
2 ES0105717005... ► Artikel lesen | |
INCYTE | 52,80 | 0,00 % | Incyte Corporation: Incyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekannt | Randomisierte Phase-2-Studie erreichte den primären Endpunkt bei Patienten mit Hidradenitis suppurativa (HS) und untermauert Wirksamkeits- und Sicherheitsprofil von Ruxolitinib-Creme Ergebnisse... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 88,78 | +0,25 % | Edwards Lifesciences' chair Michael Mussallem retires from board | ||
WPD PHARMACEUTICALS | 0,027 | 0,00 % | WPD Pharmaceuticals Inc: WPD Pharmaceuticals files 2021, 2022 results | ||
HALEON | 4,000 | +3,37 % | NSE - Haleon plc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
BIONANO GENOMICS | 1,130 | +3,67 % | Bionano Genomics: Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024 | Q4 2023 revenue was $10.7 million, which represents a 30% increase over Q4 2022FY 2023 revenue was $36.1 million, which represents a 30% increase over FY 2022Reached installed base of 326 optical... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 0,218 | 0,00 % | Why Tonix Pharmaceuticals Stock (TNXP) Is Getting Obliterated | ||
GRIFOLS | 8,434 | +0,07 % | CNMV requires Grifols to disclose the calculation of EBITDA |